Comparing the current results to its competitors, Olema Pharmaceuticals Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 8.97 %, recorded in the same quarter.
Olema Pharmaceuticals Inc , slower than the average decrease reported by the company's competitors of -18.49 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -18.49 %
Olema Pharmaceuticals Inc 's Comment on Competition and Industry Peers
The company operates in the biotechnology and pharmaceutical industries, which are characterized by rapid technological advancement and significant competition. Competitors include major and specialty pharmaceutical and biotechnology companies, academic research institutions, governmental agencies, and public and private research institutions. The company faces risks related to patent protection, including potential challenges, narrowing, circumvention, or invalidation of patents, which may limit its ability to prevent competitors from marketing related product candidates. Additionally, risks related to trademarks and trade names may affect brand identity and market recognition if challenged or infringed. The company has not yet established a commercial organization and plans to build commercial infrastructure and seek partnerships to support the development and commercialization of its product candidates, including palazestrant and OP-3136.
April 25, 2025
Factual Olema Oncology, a clinical-stage biopharmaceutical company specialized in developing targeted therapies for breast cancer and other malignancies, has announced significant preclinical findings regarding its investigational drug OP-3136. The data, which highlight the compound s anti-tumor activity across various solid tumor models, will be presented during a late-breaking poster session at the American Association for Cancer Research (AACR) Annual Meeting, scheduled to take place in Chicago, Illinois, from April 25 to April 30, 2025.OP-3136 is a novel small molecule designed to potently and selectively inhibit lysine acetyltransferase 6 (KAT6), an enzyme implicated in various oncogenic processes. Rec...
December 10, 2024
The latest clinical results for the combination therapy of palazestrant, an oral selective estrogen receptor degrader (SERD), and ribociclib, a CDK4/6 inhibitor, highlight potential advancements in treating estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer. Presented by Olema Pharmaceuticals at the San Antonio Breast Cancer Symposium (SABCS) 2024, these results could mark a significant development in targeted cancer therapy options. Study OverviewThe ongoing Phase 1b/2 trial, which commenced earlier this year, aims to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of the combined regimen of palazestra...
San Francisco-based biopharmaceutical company Olema Pharmaceuticals, Inc. (Nasdaq: OLMA), also known as Olema Oncology, is making waves in the field of women s cancers with its latest announcement. The company has revealed interim results from their ongoing Phase 1b/2 clinical study of palazestrant (OP-1250) in combination with CDK4/6 inhibitors ribociclib and palbociclib. These results were showcased at the prestigious San Antonio Breast Cancer Symposium (SABCS), held at the Henry B. Gonzalez Convention Center in Texas. Originally planned for disclosure on December 7, 2023, the 2023 SABCS published the posters ahead of schedule on December 5, 2023. Full data of the studies will be presented on...
Publicly Traded Peers of Olema Pharmaceuticals Inc
Iovance Biotherapeutics inc Share Performance
+99.29%
This Quarter
Iovance Biotherapeutics inc
Profile
Iovance Biotherapeutics Inc operates on a business model centered around developing and commercializing novel cancer immunotherapy treatments. The company focuses on utilizing its proprietary Tumor Infiltrating Lymphocyte (TIL) therapy, which involves collecting and expanding a patient's own immune cells to target and kill cancer cells. Iovance primarily seeks to advance its TIL therapy candidates through clinical trials and collaborations while aiming to provide effective and personalized treatment options for cancer patients.
Nurix Therapeutics Inc's business model involves developing targeted protein degradation therapies to treat diseases by modulating the body's cellular protein levels.
NextCure Inc is a biopharmaceutical company that operates with a unique business model. They focus on discovering and developing novel immunomedicines to treat various forms of cancer and other immune-related diseases. With a focus on developing innovative therapies that target immune cells, NextCure aims to provide effective and personalized treatment options for patients in need.
Sources:
Olema Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Olema Pharmaceuticals Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
